Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia ; volume:9 ; number:1 ; day:13 ; month:5 ; year:2021 ; pages:1-6 ; date:12.2021
Biomarker Research ; 9, Heft 1 (13.5.2021), 1-6, 12.2021
- Urheber
-
Mistry, Jayna J.
Hellmich, Charlotte
Lambert, Amelia
Moore, Jamie A.
Jibril, Aisha
Collins, Angela
Bowles, Kristian M.
Rushworth, Stuart A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-021-00291-y
- URN
-
urn:nbn:de:101:1-2021091321360658241607
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mistry, Jayna J.
- Hellmich, Charlotte
- Lambert, Amelia
- Moore, Jamie A.
- Jibril, Aisha
- Collins, Angela
- Bowles, Kristian M.
- Rushworth, Stuart A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Daratumumab
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines